# Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

> **NCT03428373** · PHASE2,PHASE3 · UNKNOWN · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 57 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
- Multiple Myeloma Stage II
- Multiple Myeloma Stage I
- Multiple Myeloma With Failed Remission
- Multiple Myeloma Stage III

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** ASA

## Key facts

- **NCT ID:** NCT03428373
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-17
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-09-30
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428373, "Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03428373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*